ORIGIN-1试验:类器官指导的N-of-1试验评估罕见非F508del突变囊性纤维化患者对CFTR调节剂反应的方案
ORIGIN-1试验旨在确定类器官指导的N-of-1试验能否预测并证明ETI对携带罕见CFTR突变患者的临床反应。基于体外测试合格者进入干预阶段,随机接受盲法ETI或安慰剂14天治疗块,间隔14天洗脱,至少两个周期。该精准医学路径可能扩展CFTR调节剂至罕见突变人群。
要点
- 类器官体外药敏可指导罕见CFTR突变患者的ETI个体化试验。
- N-of-1随机盲法交叉设计,治疗块14天,洗脱14天,至少两周期。
- 目标人群为传统平行组试验难以纳入的罕见非F508del突变患者。
核心结论
- 类器官指导的N-of-1试验或可预测并证明ETI对罕见CFTR突变患者的临床反应,扩展调节剂应用。
研究设计与样本
- 干预性N-of-1试验,基于体外类器官测试筛选合格参与者进入干预阶段。
- 参与者随机接受盲法ETI或安慰剂14天治疗块,洗脱14天后交叉至另一治疗,至少两个周期,最多四个周期。
关键数值与推荐
- 治疗块时长14天,洗脱期14天,一个治疗周期含一个ETI块、一个安慰剂块及中间洗脱期。
- 参与者完成至少两个、最多四个连续治疗周期,取决于计划的中期分析结果。
临床怎么用
- 为罕见CFTR突变患者提供基于类器官药敏的个体化ETI试用路径,辅助高成本调节剂的精准使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cystic fibrosis (CF) is a genetic condition caused by mutation of the cystic fibrosis transmembrane regulator (CFTR) gene. Recently licensed modulator therapies target the defective CFTR protein and have transformed the formerly life-limiting trajectory of people with CF (pwCF). elexacaftor/tezacaftor/ivacaftor (ETI) has shown outstanding clinical efficacy in pwCF homozygous for F508del (approximately 50%), and those with a F508del mutation paired with any of the > 2000 other mutations identified in the CFTR gene (heterozygous pairing). However, clinical response to modulators is variable and people with rare CF mutations are often excluded from modulator access worldwide. The ORIGIN-1 trial aims to determine whether an organoid-guided n-of-1 trial can predict and demonstrate clinical response to ETI in pwCF with rare mutations. METHODS: Based on the in vitro testing, participants will be eligible to enter the interventional phase of the trial. Participants will be administered blinded study drug (i.e. ETI or placebo) for a 14-day treatment block followed by a 14-day washout period prior to beginning the alternate treatment, again for a 14-day period. A treatment cycle will be defined as one ETI treatment block, one placebo treatment block and the intervening washout period. Treatment blocks sequence will be randomly assigned. Participants will complete a minimum of two treatment cycles and up to four consecutive cycles depending on the results of planned interim analyses. DISCUSSION: The ORIGIN-1 trial is designed to demonstrate a precision medicine approach that targets CFTR modulator therapy to ensure the optimal use of these very high-cost therapies. This pathway may expand the application of CFTR modulators to include pwCF with rare mutations of the CFTR gene for whom CFTR modulators' efficacy has not been (and are unlikely to ever be) proven by conventional, parallel-group clinical trials. We anticipate that a personalised organoid model that measures patient-specific CFTR responses to modulators in vitro will enable the reliable identification of pwCF with these rare CFTR mutations who are likely to respond to existing modulator therapy. TRIAL REGISTRATION: Australia New Zealand Clinical Trials Registry (ANZCTR) ID: ACTRN12623001136695 Registered on November 03, 2023.
引用
- Sabino LR, Kaiko GE, Dorahy D, et al. ORIGIN-1 trial: study protocol for an organoid-guided N-of-1 trial evaluating CFTR modulator response in cystic fibrosis with rare non-F508del mutations. Trials. 2026. PMID: 42298697. doi:10.1186/s13063-026-09789-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。